Varicose veins run in families, and genetics is a major reason why. A large study of roughly half a million people estimated that heritable factors account for about 28% of the variation in who develops varicose veins and who does not. If one of your parents was treated for varicose veins, your own risk roughly doubles compared to the general population, and if two or more close relatives were affected, the risk climbs higher still. But the genetics involved are not simple: researchers have identified well over a hundred spots in the genome that each nudge risk up or down by a small amount, meaning varicose veins are a classic case where many genes interact with lifestyle and environmental exposures to produce the final outcome.
How Strong Is the Family Connection?
The most comprehensive look at family risk comes from a nationwide Swedish study that tracked hospital records across entire families. Offspring who had one parent treated for varicose veins were about 2.4 times more likely to need hospital treatment themselves. People with one affected sibling faced roughly 2.9 times the risk. And those with two or more affected siblings, or two affected parents, had nearly six times the risk of someone with no family history at all.1PubMed. Family history and risk of hospital treatment for varicose veins in Sweden
An interesting detail in that same study: spouses of people with varicose veins were also at higher risk, around 1.7 times that of the general population. Married couples do not share genes, but they do share households, diets, activity levels, and standing habits. That spousal signal is a reminder that family clustering is not purely genetic. Shared environments amplify the pattern. Still, the sibling and parent risks were far higher than the spousal risk, which suggests genes are the dominant player in family clustering.
The UK Biobank analysis of nearly 500,000 participants confirmed the genetic side more directly: statistical modeling estimated that heritable factors explained 28% of the population variance in varicose vein disease.2PubMed Central. Clinical and Genetic Determinants of Varicose Veins That is a meaningful share, comparable to the heritability of many common conditions like type 2 diabetes or high blood pressure. It means that if you lined up a large group of people, roughly a quarter of the variation in who develops varicose veins would trace back to genetic differences, with the remaining three-quarters driven by age, sex, body weight, occupational exposures, pregnancies, and other non-genetic factors.
Many Genes, Small Effects
Varicose veins are not caused by a single “varicose vein gene.” Genome-wide association studies comparing tens of thousands of people with varicose veins to over a million disease-free controls have identified 139 risk loci, each one a spot in the genome where a particular DNA variant slightly increases or decreases susceptibility.3PubMed. Genetics of varicose veins reveals polygenic architecture and genetic overlap with arterial and venous disease A separate study using exome sequencing (which focuses on the protein-coding portions of DNA) found 36 common variants across 34 genes and three rare-variant genes, with replication in an independent Finnish cohort.4PubMed Central. Exome sequencing identifies novel genetic variants associated with varicose veins
This polygenic architecture explains why varicose veins do not follow a clean Mendelian pattern the way, say, sickle cell disease does. You do not inherit one broken copy and inevitably develop the condition. Instead, you inherit a collection of small-effect variants, some raising risk, some lowering it. On top of that genetic hand, your environment and behavior tilt the odds further. Two siblings can share many of the same risk variants and still end up with different outcomes because one works a desk job while the other stands all day.
The PIEZO1 Story
Among the 139 risk loci, one gene stands out: PIEZO1. It achieved the strongest statistical signal in the exome sequencing study and was significant in both common-variant and rare-variant analyses.4PubMed Central. Exome sequencing identifies novel genetic variants associated with varicose veins PIEZO1 encodes a mechanosensitive ion channel, essentially a protein in the cell membrane that opens in response to physical stretching or fluid flow. It sits on the inner lining of blood vessels and helps cells “sense” how blood is moving past them.
Recent lab work has shown that varicose veins lose PIEZO1 expression at both the RNA and protein levels. When endothelial cells are exposed to the kind of disturbed, back-and-forth blood flow that develops in veins with failing valves, PIEZO1 activity drops sharply. This loss appears to reduce a downstream protective signal called KLF2, which triggers the cells to transform in ways that weaken the vein wall.5PubMed Central. Altered venous flow drives endothelial to mesenchymal transition in varicose veins by suppressing PIEZO1-KLF2 signaling
Interestingly, mouse experiments have found that deleting PIEZO1 from the endothelium actually reduced experimental varicose veins and inflammation, while pharmacologically activating PIEZO1 worsened them.6PubMed. Endothelium Piezo1 deletion alleviates experimental varicose veins by attenuating perivenous inflammation That seems paradoxical: one study finds less PIEZO1 in human varicose tissue, while another finds that turning it off in mice helps. The likely explanation is that context matters enormously. In healthy veins with smooth laminar flow, PIEZO1 is protective. In diseased veins with turbulent flow, PIEZO1 may be overactivated in certain cell layers, driving inflammation. Researchers are still working out which direction to push this target, and it is a reminder that promising genetic findings do not translate into treatments overnight.
Venous Valves and the FOXC2 Gene
Varicose veins develop when the one-way valves inside veins stop working properly, allowing blood to pool and stretch the vessel walls. The gene FOXC2 has been directly linked to this valve failure. People carrying mutations in FOXC2 have a much higher rate of valve incompetence in both the superficial veins near the skin surface and the deep veins running through the leg muscles.7PubMed. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb FOXC2 was one of the first genes shown to be important for normal development and maintenance of venous valves.
Developmental studies have revealed that FOXC2 is expressed on one side of the valve leaflet, while another transcription factor called NFATc1 is expressed on the opposite side. The two proteins are not found in the same cells; they mark distinct populations on the upstream and downstream faces of the leaflet, working with different gap-junction proteins to organize the valve’s structure.8Developmental Biology. Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice Mouse experiments have confirmed that disrupting both FOXC2 and the calcineurin/NFAT signaling pathway together leads to abnormal valve organization.9PubMed Central. Human venous valve disease caused by mutations in FOXC2 and GJC2 In other words, the genetic blueprint for building functional venous valves involves an intricate choreography of gene expression, and disruptions at multiple points can tip toward valve failure.
What Happens Inside the Vein Wall
Genes set the stage, but the physical changes that produce a varicose vein play out in the vein wall itself. Two structural proteins, elastin and collagen, are the main scaffolding that keeps veins strong yet flexible. In varicose veins, these proteins are degraded and their balance is disrupted by enzymes called matrix metalloproteinases (MMPs).10Gene Reports. Molecular and genetic insights into varicose veins The result is a wall that is weaker and less elastic, which stretches under the pressure of pooling blood and bulges outward.
Chronic venous disease involves ongoing inflammation, and the MMP system is central to that process. An imbalance between MMPs and their tissue inhibitors (TIMPs) promotes breakdown of the vein wall’s structural matrix in both early and late stages.11PubMed Central. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease You might expect that genetic variants in MMP genes would be strong risk factors, but at least one study of common MMP gene polymorphisms found no significant association with varicose vein risk.12PubMed. Polymorphism of Matrix Metalloproteinases Genes MMP1, MMP2, MMP3, and MMP7 and the Risk of Varicose Veins of Lower Extremities That is not unusual with complex diseases. The enzymes clearly play a role in disease progression, but the genetic variants that turn those enzymes up or down may lie in regulatory regions that those particular studies did not test, or the effect may come from a combination of multiple genes rather than a single variant.
The smooth muscle cells embedded in the vein wall also behave differently in varicose tissue. Cells taken from varicose segments show higher rates of proliferation, migration, and aging compared to cells from non-varicose segments of the same person’s veins.13PubMed. Phenotypic and functional transformation in smooth muscle cells derived from varicose veins These cells have shifted to a more “synthetic” state, producing matrix components haphazardly rather than maintaining the orderly structure of a healthy vessel. Whether this transformation is a cause of varicose veins or a consequence of the altered mechanical environment is still debated, but it likely feeds back in both directions.
Inflammation Genes and Epigenetics
Beyond structural genes, inflammation-related variants also contribute. A study of over 700 patients found that variants in genes controlling inflammatory pathways, including HIF1A, TNF, NFKB1, and IL6, were associated with the risk of primary varicose veins.14PubMed. Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians A Mendelian randomization study added evidence that higher circulating levels of certain inflammatory signaling molecules, including VEGF-A and caspase-8, are associated with increased varicose vein risk.15PubMed Central. Exploring causal correlations between inflammatory cytokines and varicose veins This suggests the link between inflammation and varicose veins is not just circumstantial; there appears to be a causal arrow running from inflammatory biology to vein disease.
There is also an emerging epigenetic layer to the story. When the inner lining of a vein is exposed to the disturbed, oscillating blood flow that develops behind a failing valve, the DNA in the vein wall cells acquires changes in methylation patterns. These chemical marks do not alter the DNA sequence, but they change which genes are turned up or down. Researchers have found distinct methylation changes in each layer of the vein wall under these conditions, suggesting that abnormal flow may lock in gene expression changes that push the vein further toward varicose transformation.16PubMed Central. Epigenome-Wide Changes in the Cell Layers of the Vein Wall When Exposing the Venous Endothelium to Oscillatory Shear Stress In this way, even a genetically healthy vein could be reprogrammed by its mechanical environment over time.
Non-Genetic Risk Factors That Interact with Your Genes
Since about 72% of the variation in varicose vein risk is not heritable, non-genetic factors clearly matter a great deal. Prolonged standing or walking at work is one of the best-studied occupational risks. A 12-year Danish prospective study estimated that workers in standing-intensive jobs faced roughly 1.8 times the risk of hospitalization for varicose veins compared to workers in other jobs, even after adjusting for body weight and smoking. The researchers estimated that occupational standing accounted for about 23% of cases among those workers.17PubMed Central. Prolonged standing at work and hospitalisation due to varicose veins: a 12 year prospective study of the Danish population
Other well-established risk factors include obesity, older age, female sex, and pregnancy. These are likely not independent of genetics. A person who inherits weaker vein walls may tolerate years of standing without developing varicose veins if they are lean and active, while the same genetic profile combined with excess weight and prolonged standing may cross the threshold into disease. Genes load the gun; lifestyle pulls the trigger, as the saying goes.
Why Varicose Veins Are More Common in Women
Women develop varicose veins more often than men, and hormones appear to be a significant reason. The walls of varicose veins in premenopausal women show a marked increase in estrogen receptors compared to healthy veins. This increase is spread uniformly through all three layers of the vein wall.18PubMed Central. Increase and Redistribution of Sex Hormone Receptors in Premenopausal Women Are Associated with Varicose Vein Remodelling Animal studies have confirmed that female veins contain higher amounts of multiple types of estrogen receptors than male veins, which affects how the vessels relax and respond to pressure.19PubMed Central. Estrogen receptor-mediated enhancement of venous relaxation in female rat
Beyond hormone receptors, gene expression patterns differ between men and women with varicose veins. A study examining sex-specific gene expression found that sex was a moderate to strong predictor for the expression of genes like TIMP1 and STK38L in varicose vein tissue, with expression levels differing between male and female patients.20PubMed Central. Sex-Specific Gene Expression Differences in Varicose Veins TIMP1 is directly involved in regulating the MMP enzymes that break down vein wall structure, so having different TIMP1 expression could mean that the vein wall remodeling process itself differs between the sexes. Pregnancy adds further risk through a combination of increased blood volume, hormonal surges, and mechanical pressure from the uterus on pelvic veins, but the underlying sex-based differences in vein biology are present even apart from pregnancy.
Shared Genetics with Blood Clots
If your family has a history of varicose veins, there may be an overlapping predisposition to venous blood clots. A Swedish nationwide family study found that people whose siblings had varicose veins were about 30% more likely to develop venous thromboembolism (VTE), and the reverse was also true: siblings of VTE patients had a 30% higher risk of varicose veins. When two or more siblings had either condition, the cross-risk climbed further.21PubMed Central. Venous thromboembolism and varicose veins share familial susceptibility
A separate study found that patients with varicose veins, and especially those who had progressed to venous ulcers, had significantly higher rates of inherited blood-clotting disorders (thrombophilias) than matched controls without vein disease.22PubMed. Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls The researchers proposed that inherited tendencies toward clotting promote subclinical thrombosis that damages venous valves over time, setting the stage for both conditions. This overlap is worth knowing about because it means a strong family history of varicose veins might warrant a conversation with your doctor about clotting risk, not just cosmetic concerns.
Rare Genetic Syndromes That Include Varicose Veins
The discussion so far has been about common, garden-variety varicose veins with their complex polygenic inheritance. There are also rare genetic syndromes in which varicose veins appear as one feature of a broader pattern. Klippel-Trénaunay syndrome is the most recognized. It involves a combination of varicose veins in unusual locations, skin-level vascular malformations (often appearing as port-wine birthmarks), and overgrowth of soft tissues and bones in one limb.23PubMed Central. The Klippel-Trénaunay Syndrome in 2022: Unravelling Its Genetic and Molecular Profile and Its Link to the Limb Overgrowth Syndromes The varicose veins in Klippel-Trénaunay tend to appear early in life and in anatomically atypical positions, distinguishing them from the superficial leg veins that affect millions of adults.24Journal of Vascular Surgery: Venous and Lymphatic Disorders. Diagnosis and management of the venous malformations of Klippel-Trénaunay syndrome
These rare conditions are caused by specific mutations with large effects, quite different from the many small-effect variants behind typical varicose veins. They are worth mentioning because a young person with prominent varicose veins and limb asymmetry may have a syndromic cause that requires different management. But for the vast majority of people wondering whether their varicose veins are hereditary, the answer lies in common genetic variation interacting with age, sex, body composition, and daily activity.
Can Genetic Research Lead to Better Treatments?
Current treatments for varicose veins are overwhelmingly mechanical: compression stockings, procedures that seal or strip the affected vein, and lifestyle changes to reduce venous pressure. These work well for symptoms, but they do not address the underlying biology, which is why recurrence is common. The hope is that genetic and molecular research will eventually point toward drugs that could prevent vein wall deterioration or improve valve function.
A Mendelian randomization analysis has identified five circulating proteins, including POSTN, LUM, and RSPO3, whose genetically predicted levels are associated with varicose vein risk, suggesting they could be druggable targets.25PubMed Central. Identification of potential drug targets for varicose veins The PIEZO1 findings offer another potential avenue, though as discussed earlier, the direction in which that target should be pushed is not yet clear. Omics studies are also mapping which microRNAs regulate the expression of vein-disease genes, adding another layer of potential intervention points.26PubMed Central. Omics Data Integration Uncovers mRNA-miRNA Interaction Regions in Genes Associated with Chronic Venous Insufficiency
None of this is anywhere near the clinic yet. Drug development from genetic target to approved therapy takes a decade or more on a good day, and varicose veins, while extremely common and sometimes debilitating, have not attracted the pharmaceutical investment that conditions like cancer or cardiovascular disease have. For now, the practical value of knowing your genetic risk is in motivation: if varicose veins run heavily in your family, you have more reason to maintain a healthy weight, stay active, avoid prolonged static standing when possible, and use compression stockings when your work or travel demands it. The genes may be fixed, but the non-genetic 72% of risk leaves real room to maneuver.